Integrated Regulation of Hepatic Lipid and Glucose Metabolism by Adipose Triacylglycerol Lipase and FoxO Proteins  by Zhang, Wenwei et al.
ArticleIntegrated Regulation of Hepatic Lipid and Glucose
Metabolism by Adipose Triacylglycerol Lipase and
FoxO ProteinsGraphical AbstractHighlightsd FoxO1 regulates expression of ATGL lipase and G0S2, its
inhibitor, in the liver
d FoxO1 promotes intrahepatic lipolysis and FAO via ATGL-
dependent effects
d FoxO1 effects on glucokinase and PEPCK gene expression
are ATGL dependent
d ATGL-dependent lipolysis regulates glucose/lipid
metabolism downstream from FoxOZhang et al., 2016, Cell Reports 15, 349–359
April 12, 2016 ª2016 The Authors
http://dx.doi.org/10.1016/j.celrep.2016.03.021Authors
Wenwei Zhang, So Young Bu,
Mara T. Mashek, ...,
Christopher B. Newgard,
Douglas G. Mashek, Terry G. Unterman
Correspondence
dmashek@umn.edu (D.G.M.),
unterman@uic.edu (T.G.U.)
In Brief
FoxO proteins are major targets of insulin
that regulate hepatic glucose
metabolism. Zhang et al. report that FoxO
proteins also promote triacylglycerol
catabolism through regulation of ATGL
and its inhibitor, G0S2, and that ATGL-
dependent lipolysis plays an important
role in mediating the effects of FoxO on
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Metabolism is a highly integrated process that is
coordinately regulated between tissues and within
individual cells. FoxO proteins are major targets of
insulin action and contribute to the regulation of
gluconeogenesis, glycolysis, and lipogenesis in the
liver. However, the mechanisms by which FoxO pro-
teins exert these diverse effects in an integrated
fashion remain poorly understood. We report that
FoxO proteins also exert important effects on intra-
hepatic lipolysis and fatty acid oxidation via the
regulation of adipose triacylglycerol lipase (ATGL),
which mediates the first step in lipolysis, and its
inhibitor, the G0/S1 switch 2 gene (G0S2). We also
find that ATGL-dependent lipolysis plays a critical
role in mediating diverse effects of FoxO proteins in
the liver, including effects on gluconeogenic, glyco-
lytic, and lipogenic gene expression andmetabolism.
These results indicate that intrahepatic lipolysis
plays a critical role in mediating and integrating the
regulation of glucose and lipid metabolism down-
stream of FoxO proteins.
INTRODUCTION
FoxO transcription factors are major targets of insulin action. In-
sulin stimulates the phosphorylation of three residues in FoxO
proteins by Akt, corresponding to T24, S256, and 319 in human
FoxO1. Phosphorylation at these sites promotes the binding of
14-3-3 proteins, which mask the DNA-binding domain and
nearby nuclear localization signals, thereby disrupting the ef-
fects of FoxO proteins on gene expression and promoting their
sequestration in the cytoplasmic compartment (Brunet et al.,This is an open access article under the CC BY-N1999; Zhao et al., 2004). In the liver, FoxO proteins contribute
to the regulation of multiple metabolic pathways involved in the
response to fasting, including gluconeogenesis (GNG), glycol-
ysis, and lipogenesis (Haeusler et al., 2014; Xiong et al., 2013;
Zhang et al., 2006, 2012), and suppressing hepatic FoxO1 func-
tion is critical for the ability of insulin to regulate hepatic glucose
production and maintain glucose homeostasis (Dong et al.,
2008; O-Sullivan et al., 2015; Titchenell et al., 2015). However,
little is known regarding the role of FoxO proteins in regulating
triacylglycerol (TAG) catabolism in the liver.
FoxO proteins promote TAG catabolism in adipose tissue
by stimulating the expression of adipose TAG lipase (ATGL)
(Chakrabarti and Kandror, 2009), which mediates the first step
in lipolysis, after which other lipases, including hormone-sensi-
tive lipase (HSL) and monoacylglycerol lipase (MAGL), promote
the removal of additional fatty acids from the glycerol back-
bone of TAG (Coleman and Mashek, 2011; Zechner et al.,
2009). Initially identified in adipose tissue (Zimmermann et al.,
2004), ATGL plays an important role in regulating TAG turnover
in many tissues. In the liver, overexpressing ATGL decreases
TAG content and promotes fatty acid oxidation (FAO) (Ong
et al., 2011; Turpin et al., 2011). Conversely, disrupting hepatic
ATGL expression promotes steatosis while improving glucose
tolerance and insulin sensitivity (Kienesberger et al., 2009; Ong
et al., 2013), indicating that regulating intrahepatic TAG catabo-
lismmay be important for the ability of insulin tomaintain glucose
homeostasis. FoxO proteins interact with response elements in
the ATGL promoter and stimulate ATGL expression in adipose
tissue (Chakrabarti and Kandror, 2009). However, the role of
FoxO proteins in regulating hepatic ATGL expression and activ-
ity, and the role of ATGL in mediating effects of FoxO proteins on
other aspects of metabolism in the liver, are less clear.
ATGL activity is inhibited by interaction with the G0/G1 switch-
2 protein (G0S2) (Yang et al., 2010). Consistent with its role as a
physiologically relevant inhibitor of ATGL, altering G0S2 expres-
sion in the liver is associated with changes in TAG content andCell Reports 15, 349–359, April 12, 2016 ª2016 The Authors 349
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. ATGL and G0S2 Gene Expression
(A) FoxO1 Tgn mice. Relative ATGL and G0S2
mRNA levels in liver of WT (solid bar) and FoxO1
Tgn (open bar) mice 6 hr after refeeding (n = 4–6).
(B) Western blot. ATGL, G0S2, and tubulin proteins
in liver were measured by western blot in refed WT
and Tgn mice.
(C) FoxO KOmice. Relative ATGL and G0S2 mRNA
levels in FoxOfl/fl (solid bar) and FoxO KO (open bar)
mice (n = 5).
(D) Effects of FoxO1 in hepatoctyes. Relative
ATGL and G0S2 mRNA levels in primary hepato-
cytes from WT mice transfected with adenovirus-
expressing (Ad)-TSS/A-FoxO1 (open bar) or GFP
(Ad-GFP, solid bar) (n = 4).
(E) Regulation by insulin. ATGL (left) and G0S2
(right) mRNA levels in primary hepatocytes treated
with or without 100 nM insulin (n = 3).
(F) FoxO KO hepatocytes. ATGL (left) and G0S2
(right) mRNA levels were measured in hepatocytes
isolated from FoxOfl/fl or FoxO KO mice following a
4-hr treatment with (open bar) or without (solid bar)
insulin (n = 3).
Statistical significance (*p < 0.05) was determined
by Student’s t test when only two groups (Tgn
versus WT) were compared or by ANOVA when
multiple comparisons were made. Bars that
are labeled with different letters (a, b, c, or d)
differ significantly from each other. Data indicate
mean ± SEM.FAO (Wang et al., 2013; Zhang et al., 2014). Insulin has been re-
ported to stimulate G0S2 expression in adipose tissue, but the
mechanism mediating this effect remains unknown (Heckmann
et al., 2013). Gene profiling studies that we previously performed
in transgenic (Tgn) mice suggested that hepatic expression of
G0S2 may be suppressed by FoxO1 (Zhang et al., 2006). Based
on these observations, we asked whether FoxO proteins stimu-
late ATGL and suppress G0S2 expression and whether ATGL-
dependent lipolysis contributes to other effects of FoxO proteins
in the liver. Our results show that FoxO proteins stimulate ATGL
and suppress G0S2 expression in the liver and that ATGL-
dependent lipolysis plays an important role in mediating effects
of FoxO proteins on both lipid and glucose metabolism in the
liver, including effects on glycolysis, lipogenesis, and GNG.
RESULTS
FoxO Proteins Regulate ATGL and G0S2 in Liver
ATGL and G0S2mRNA and protein levels were measured in Tgn
mice expressing TSS/A-FoxO1 in the liver. All three FoxO1 Akt350 Cell Reports 15, 349–359, April 12, 2016phosphorylation sites (T24, S256, and
S319) have been replaced by alanines,
so that the function of TSS/A-FoxO1 is
not inhibited by insulin action and Akt.
As shown in Figures 1A and 1B, hepatic
ATGL mRNA and protein levels were
increased and G0S2 mRNA and protein
levels were decreased in liver-specific
TSS/A-FoxO1 Tgn mice, compared towild-type (WT) littermates. Conversely, hepatic ATGL expression
was reduced and G0S2 expression was increased in liver-
specific FoxO knockout (KO) mice, in which the expression of
FoxO1, FoxO3, and FoxO4 had been disrupted in the liver,
compared to floxed controls (FoxOfl/fl) (Figure 1C), demon-
strating that endogenous FoxO proteins promote ATGL and
suppress G0S2 expression in the liver.
FoxO1 stimulated ATGL and suppressed G0S2 expression in
primary hepatocytes from WT mice (Figure 1D), showing that
FoxO1 promotes ATGL and inhibits G0S2 expression in a cell-
autonomous fashion. Conversely, insulin, which inhibits the
effects of FoxO proteins on gene expression, reduced ATGL
mRNA levels by 60% and increased G0S2 expression -fold
in WT hepatocytes (Figure 1E). ATGL expression was decreased
in hepatocytes from FoxO KO versus FoxOfl/fl mice, and there
was no additional effect of insulin on ATGL mRNA levels in
FoxO KO hepatocytes (Figure 1F, left panel). Conversely, G0S2
expression was6-fold higher in FoxO KO versus FoxOfl/fl hepa-
tocytes, and the ability of insulin to stimulate G0S2 expression
was markedly reduced in hepatocytes from FoxO KO (36%
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Figure 2. TAG Catabolism in Hepatocytes
(A) ATGL-dependent effects of FoxO1. TAG
turnover (left) and FAO (accumulation of ASMs
in hepatocyte conditioned medium) (right) were
measured in [1-14C]oleate-loaded hepatocytes
following transfection of adenovirus-expressing
control/scrambled shRNA or ATGL shRNA plus
adenovirus-expressing TSS/A-FoxO1 (open bars)
or GFP (solid bars) (n = 3).
(B) Co-expression of G0S2. TAG turnover (left)
and FAO (right) in hepatocytes transfected with
adenovirus ATGL shRNA or control/scrambled
shRNA plus adenovirus-expressing TSS/A-FoxO1
(open bars) or GFP (solid bars) (n = 3).
(C) Lipid droplets. Hepatocytes expressing TSS/
A-FoxO1 or GFP plus G0S2 or GFP were stained
with oil red O to visualize lipid droplets.
Statistical significance (p < 0.05) was determined
by ANOVA, and bars that are labeled with different
letters (a, b, c, or d) differ significantly from each
other. Data indicate mean ± SEM.increase) versus FoxOfl/fl (3-fold increase) mice (Figure 1F, right
panel). These results show that FoxO proteins regulate and
mediate the effects of insulin on ATGL and G0S2 expression in
the liver.
ATGL-Dependent Effects of FoxO1 on TAGTurnover and
FAO in Hepatocytes
Pulse-chase studies showed that FoxO1 stimulated [1-14C]
oleate-labeled TAG turnover (Figure 2A, left panel) and the oxida-
tion of hydrolyzed fatty acids (Figure 2A, right panel) in isolated
hepatocytes. Knocking down ATGL reduced basal TAG turn-
over and FAO by 50%–60% and disrupted the effects of TSS/
A-FoxO1. Co-expressing G0S2, which inhibits ATGL activity,
also reduced basal TAG turnover and FAO, but not to the same
extent as disrupting ATGL expression (Figure 2B). Rescuing
G0S2 expression also disrupted the effect of FoxO1 on TAG
turnover and reduced the effect of FoxO1 on FAO by75% (Fig-
ure 2B). FoxO1 also promoted the depletion of lipid droplets
in hepatocytes, and co-expression of G0S2 also blocked this ef-
fect (Figure 2C). These results show that FoxO1 promotes TAG
turnover and FAO in liver cells in an ATGL-dependent fashion.
ATGL-Dependent Effects of FoxO1 on TAG Catabolism
and FAO In Vivo
Treatment with adenovirus-expressing ATGL-specific short
hairpin RNA (shRNA) suppressed ATGLmRNA and protein levels
in the liver of FoxO1 Tgn and wild-type mice (Figures 3A and 3B),
but not in adipose tissue (Figure S2), confirming that the ATGL
knockdown (KD) is liver specific. ATGL KD increased liver TAG
content in WT mice (Figure 3C), consistent with previous studies
(Ong et al., 2011, 2013). Liver TAG content was low in Tgn versus
WTmice and was restored to WT levels by ATGL KD (Figure 3C),
indicating that ATGL-dependent lipolysis contributes to effects
of FoxO1 on liver TAG content.CPlasma beta-hydroxybutyrate (BHB)
levels were increased in briefly (4 hr)
fasted Tgn versus WT mice, and knockingdown ATGL reversed this effect (Figure 3D), indicating that
FoxO1 promotes FAO in the liver in an ATGL-dependent fashion.
Circulating levels of non-esterified fatty acids (NEFAs) were
reduced in Tgn versus WT mice, and knocking down ATGL
reversed this effect (Figure 3E), indicating that increased FAO
in Tgn mice was not due to increased availability of circulating
NEFAs. Glycerol levels were not altered in Tgn versus WT mice
(Figure 3F), suggesting that lipolysis in white adipose tissue
(WAT) was not reduced and that decreased NEFAs may reflect
increased re-esterification in WAT (Wolfe and Peters, 1987)
and/or uptake and utilization by the liver in Tgn versus WT mice.
We also considered whether FAO is increased in Tgnmice 6 hr
after refeeding, when endogenous FoxO proteins are inactive
but TSS/A-FoxO1 remains active in Tgn mice. Although BHB
levels are suppressed in both WT and Tgn refed mice (Zhang
et al., 2006), long-chain fatty acylcarnitine levels were increased
in the liver of Tgn versusWTmice, and knocking down ATGL dis-
rupted this effect (Figure 3G). This result indicates that FAO also
is increased in refed Tgn versus WTmice in an ATGL-dependent
fashion and that suppressing FoxO1 and ATGL function is
required to fully suppress intrahepatic lipolysis and FAO in the
refed state.
We also examined the expression of other genes related
to TAG turnover and FAO. The expression of G0S2 was sup-
pressed in refed Tgn versus WT mice and was partially
restored to WT levels by ATGL KD in Tgn mice (Figure 3H).
This result indicates that FoxO1 suppresses G0S2 expression
through both ATGL-dependent and -independent mecha-
nisms. Conversely, expression of HSL, which catabolizes diac-
yglycerols, was increased in Tgn versus WT mice, and ATGL
KD also reversed this effect. These results indicate that, in
addition to its direct effect on TAG turnover, ATGL also pro-
motes intrahepatic lipolysis by altering G0S2 and HSL expres-
sion downstream from FoxO1.ell Reports 15, 349–359, April 12, 2016 351
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Figure 3. TAG Catabolism in Liver
(A) ATGL KD in vivo. ATGL mRNA levels were
measured in liver in WT and Tgn mice 7 days after
tail vein injection with adenovirus-expressing con-
trol/scrambled shRNA (shCon, solid bars) or ATGL
shRNA (shATGL, open bars) (n = 4–5).
(B)Western blot. ATGL protein level in liver fromWT
and Tgn mice with or without ATGL KD.
(C) Liver TAG. TAG in refed WT and Tgn mice
7 days after ATGL KD (n = 4–5).
(D–F) Plasma levels of b-hydroxybutyrate (D), NE-
FAs (E), and glycerol (F). Plasmawas collected from
briefly (4-hr) fasted mice from WT and Tgn mice
5 days after treatment with control shRNA (shCon,
solid bar) or ATGL shRNA (shATGL, open bar)
adenovirus. Plasma BHB levels in 4-hr-fasted WT
and Tgn mice 5 days post-ATGL KD (n = 6–8).
(G) Fatty acylcarnitines. Long-chain fatty acyl car-
nitines in liver from refed WT and Tgn mice 7 days
after treatment with adenovirus-expressing
scrambled/control shRNA (shCon) or ATGL shRNA
(shATGL, n = 4–5).
(H) Lipid droplet genes. Relative levels of G0S2,
HSL, and MAGL mRNA in WT and Tgn mice 7 days
post-ATGL shRNA or control adenovirus treatment
(n = 4–5).
(I) FAO genes. CPT-1, LCAD, ACOX1, ACOT1, and
PPARa mRNA levels 7 days post-treatment with
ATGL shRNA or control adenovirus are shown (n =
4–5).
Statistical significance (p < 0.05) was determined
by ANOVA, and differences between groups are
identified by labeling with different letters (a, b, c, or
d) or by an asterisk (for fatty acyl carnitines). Data
indicate mean ± SEM.The expression of carnitine palmitoyl transferase 1 (CPT1),
which promotes translocation of fatty acyl-CoAs into mitochon-
dria, was increased 2-fold in Tgn versusWTmice, and this effect
was reversed by ATGL KD (Figure 3I). Although fatty acid activa-
tion of peroxisome proliferator receptor-a (PPARa) can promote
the expression of CPT1, the expression of other PPARa-regu-
lated genes involved in promoting FAO was not increased in
Tgn versus WT mice (Figure 3I), including very long chain acyl352 Cell Reports 15, 349–359, April 12, 2016dehydrogenase (LCAD), acyl-CoAoxidase
1 (ACOX1), and acyl-CoA thioesterase 1
(ACOT1), suggesting that other mecha-
nisms may mediate the effects of FoxO1
and ATGL on CPT1 expression.
Together, these results indicate that
ATGL promotes FAO in the liver, down-
stream from FoxO proteins by multiple
mechanisms, including direct effects
on TAG turnover and effects on gene
expression.
ATGL-Dependent and -Independent
Effects on Lipid Levels and
Lipogenesis
We also examined circulating TAG levels
in Tgn and WT mice 6 hr after refeeding,when de novo lipogenesis is stimulated in the liver. Previous
studies indicate that FoxO proteins suppress de novo lipogen-
esis in the liver and circulating TAG levels (Haeusler et al.,
2014; Zhang et al., 2006, 2012). As shown in Figure 4A,
TAG levels are reduced in Tgn versus WT mice treated with
control adenovirus, and ATGL KD increased TAG levels in
Tgn mice 3-fold, indicating that ATGL contributes to the
effects of FoxO1 on TAG levels. At the same time, ATGL KD
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Figure 4. Lipid Levels and Lipogenesis
(A) Serum TAG levels in refed male WT and Tgn mice with or without ATGL KD (n = 4–5). shATGL, adenovirus-expressing ATGL shRNA; shCon, adenovirus-
expressing control/scrambled shRNA.
(B) Cholesterol levels in refed mice with or without ATGL KD (n = 4–5).
(C). Hepatic TAG secretion. WT and Tgn mice with or without ATGL KD were treated with Tyloxapol 4 hr after refeeding. Plasma TAG level was determined 0, 40,
80, and 120 min after Tyloxapol treatment, and change in TAG level is shown. (n = 4)
(D) Lipoprotein fractionation. Plasma from refed WT and Tgn mice with or without ATGL KD was fractionated by FPLC and TAG (upper panel), and cholesterol
(lower panel) content was determined in FPLC fractions. Average values are shown for two samples from each group. Inset: western blot of apoB in FPLC
fractions 4–6 is shown.
(E) VLDL packaging genes. Liver apoB, MTTP, and TGH mRNA levels in refed mice 7 days post-ATGL KD are shown (n = 4–5).
(F) Lipogenic genes. Liver SREBP-1c, ATP citrate lyase (ACLy), acetyl-CoA carboxylase (ACC1), fatty acid synthase (FAS), stearoyl-CoA desaturase-1 (SCD1),
and glycerol-3-phosphate acyltransferase-1 (GPAT1) mRNA levels in refed mice are shown (n = 4–5).
(G) Glycolytic genes. Liver mRNA levels for Gck and pyruvate kinase in refed mice (n = 4–5).
(H) Western blot. Liver SREBP-1c, Gck, and tubulin protein levels in refed mice (see Figure S4).
(I–K) Lipogenesis. Plasma TAG levels (I) and malonyl-CoA in liver (J) were measured in refed female WT and Tgn mice 7 days after treatment with shATGL or
shCon. Deuterated water was administered 2 hr after refeeding, and tissue was harvested 4 hr later for determination of newly synthesized palmitate in liver (K)
(n = 4–5).
Statistical significance (p < 0.05) was determined by ANOVA, and differences between groups are identified by labeling with different letters (a, b, c, or d), or by an
asterisk (for Tyloxapol studies). Data indicate mean ± SEM. See also Figure S4.also increased TAG levels in WT mice by 40% (Figure 4A), so
that TAG levels were still higher in WT versus Tgn mice after
ATGL KD (Figure 4A). Adenoviral expression of G0S2 also
improved TAG levels in Tgn mice by 3-fold and increased
TAG levels by 30% in WT mice (Figure S3A). These results
indicate that ATGL-dependent lipolysis contributes to the ef-
fects of FoxO on TAG levels and that FoxO suppresses TAG
levels by both ATGL-dependent and -independent mecha-
nisms. Cholesterol levels also were low in Tgn versus WT
mice but were not affected by ATGL KD (Figure 4B) or G0S2expression (Figure S3B), indicating that the effect of ATGL
was specific for TAGs.
Studies with Tyloxapol, which inhibits the endovascular lipol-
ysis of TAG, showed that the appearance of newly secreted
TAG was reduced in Tgn versus WT mice and was restored by
ATGL KD (Figure 4C). Fractionation of plasma lipoproteins in
refed mice revealed that VLDL TAG content was decreased in
Tgn versusWTmice and restored by ATGL KD (Figure 4D, upper
panel), and western blotting showed that VLDL apolipoprotein B
(apoB) levels also were reduced in Tgn versus WT mice andCell Reports 15, 349–359, April 12, 2016 353
restored by ATGLKD (Figure 4D, inset). Since each VLDL particle
contains one apoBmolecule, this result indicates that changes in
TAG levels in Tgn mice reflect ATGL-dependent effects on he-
patic secretion of VLDL particles. VLDL (but not HDL) cholesterol
content also was reduced in Tgn versus WT mice and restored
by knocking down ATGL (Figure 4D, lower panel), consistent
with changes in VLDL particle number. These results indicate
that suppressing FoxO1 and ATGL function is important in pro-
moting hepatic VLDL production in the postprandial state.
Liver apoBmRNA levels were modestly reduced in Tgn versus
WTmice (Figure 4E) but remained low after ATGL KD (Figure 4E),
indicating that changes in apoB expression were not responsible
for the recovery of VLDL production in Tgn mice treated with
ATGL shRNA. In contrast, expression of microsomal TAG trans-
fer protein (MTTP), which promotes the packaging of TAG in
VLDL, and triacylglycerol hydrolase (TGH)/carboxylesterase 3,
which is required for VLDL secretion (Lian et al., 2012), were
reduced in Tgn versusWTmice and restored by ATGL KD. These
results indicate that changes in MTTP and TGH expression may
contribute to improved VLDL secretion and TAG levels when
ATGL is knocked down in Tgn mice.
Previous studies have shown that FoxO proteins can suppress
de novo lipogenesis by reducing glycolytic and/or lipogenic gene
expression and metabolism in the liver (Haeusler et al., 2014;
Zhang et al., 2006). As shown in Figure 4F, the expression of ste-
rol response element binding protein-1c (SREBP-1c), a major
regulator of lipogenic gene expression, and several of its down-
stream target genes (including ATP citrate lyase, acetyl-CoA
carboxylase-1, fatty acid synthase, stearoyl-CoA desaturase-1,
and glycerol-3 phosphate acyltransferase-1) were suppressed
in Tgn mice and partially restored by ATGL KD. Glucokinase
(Gck) and pyruvate kinase (L-PK) expression also were sup-
pressed in Tgn versus WT mice and largely restored by ATGL
KD (Figure 4G). Western blotting confirmed that SREBP-1c
and Gck protein levels also were largely restored to WT levels
in Tgn mice by ATGL KD (Figures 4H and S4A). Expression of
G0S2 also restored Gck and improved lipogenic gene expres-
sion in Tgn mice (Figure S3C), supporting the concept that
ATGL-dependent lipolysis contributes to the regulation of glyco-
lytic and lipogenic gene expression by FoxO proteins.
In a separate study, we examined effects on TAG levels and de
novo lipogenesis in female mice. TAG levels were decreased in
refed female Tgn versus WT mice and were partially restored
to WT levels by ATGL KD (Figure 4I), similar to males (discussed
earlier). Liver levels of malonyl-CoA levels were decreased in
refed Tgn versus WT mice and were increased by ATGL KD
(Figure 4J), consistent with increased glycolytic and lipogenic
metabolism. Studies with deuterated water showed that newly
synthesized palmitate in liver also was reduced in refed Tgn
versus WT liver, consistent with previous studies (Zhang et al.,
2006), and was improved by knocking down ATGL (Figure 4K).
The increase in newly synthesized palmitate may be underesti-
mated in Tgn mice, since hepatic secretion of VLDL also mark-
edly improved ATGL KD in Tgn mice (discussed earlier). These
results support the concept that ATGL contributes to the sup-
pression of de novo lipogenesis by FoxO1. At the same time,
since ATGL KD does not fully restore levels of TAG, malonyl-
CoA, or newly synthesized palmitate, both ATGL-dependent354 Cell Reports 15, 349–359, April 12, 2016and -independent effects appear to contribute to effects of
FoxO1 on TAG levels and de novo lipogenesis.
ATGL-Dependent and -Independent Effects of FoxO1 on
Glucose Homeostasis
We also asked whether ATGL contributes to FoxO effects on
glucose homeostasis. Glucose tolerance was impaired in 4-hr-
fasted Tgn versus WT mice, and ATGL KD restored glucose
tolerance in Tgn mice (Figure 5A), indicating that ATGL-depen-
dent lipolysis contributes to the effects of FoxO1 on glucose ho-
meostasis. At the same time, ATGL KD also improved glucose
tolerance in WT mice, consistent with previous reports (Ong
et al., 2013), so that glucose tolerance remained significantly
different in Tgn versus WT mice after ATGL KD (Figure 5A), indi-
cating that ATGL-independent mechanisms also contribute to
the effects of FoxO1 on glucose tolerance. Adenoviral expres-
sion of G0S2 in the liver of female Tgn and WT mice yielded
similar results (Figure 5B), supporting the concept that ATGL-
dependent lipolysis contributes to the effects of FoxO1 on
glucose homeostasis and that FoxO1 impairs glucose tolerance
by both ATGL-dependent and -independent mechanisms.
Pyruvate tolerance was also impaired in Tgn versus WT mice
and restored to normal by knocking down ATGL (Figure 5C),
indicating that glucose production from pyruvate may be
increased in FoxO1 Tgn mice and that ATGL contributes to
this effect. Studies in hepatocytes showed that FoxO1 in-
creases glucose production from pyruvate in isolated liver cells
and that knocking down ATGL disrupted this effect (Figure 5D),
supporting the concept that ATGL contributes to the ability of
FoxO1 to promote hepatic glucose production in a cell-auton-
omous fashion.
Given that ATGL promotes FAO downstream from FoxO1 and
FAO promotes GNG in the liver (Lewis et al., 1997; Perry et al.,
2015), we also asked whether increased FAO may contribute
to the effect of FoxO1 to promote glucose intolerance in Tgn
mice. Treatment with a low dose of etomoxir (3 mg/kg), which
is sufficient to suppress FAO in the liver (Satapati et al., 2012)
and BHB levels in briefly fasted FoxO1 Tgn mice (Figure S5A),
restored normal glucose tolerance in FoxO1 Tgn mice (Fig-
ure 5E). This result is consistent with the concept that increased
FAO in the liver contributes to effects of FoxO1 on glucose toler-
ance, although we cannot exclude the possibility that effects of
etomoxir on other tissues also may contribute to this result.
We also asked whether ATGL contributes to the effects of
FoxO proteins on glycolytic and/or gluconeogenic gene expres-
sion in briefly fastedmice. GckmRNA and protein levels are sup-
pressed in FoxO1 Tgn mice and restored by ATGL KD (Figures
5F and S4B). At the same time, ATGL KD increased Gck expres-
sion in WT mice so that Gck mRNA levels were still lower in Tgn
versus WT mice when ATGL expression is suppressed (Fig-
ure 5F). These results indicate that FoxO1 suppresses Gck
expression by both ATGL-dependent and -independent mecha-
nisms. Conversely, the expression of several genes that promote
GNG, including phosphoenolpyruvate carboxykinase (PEPCK),
peroxisome proliferator receptor gamma coactivator-1a (PGC-
1a), and pyruvate carboxylase (PC), was increased in Tgn versus
WT mice and normalized in an ATGL-dependent fashion (Fig-
ure 5F). The expression of glucose-6 phosphatase (G6pase)
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Figure 5. Glucose Tolerance and Glucose
Production
(A) Glucose tolerance: ATGL KD. Glucose toler-
ance tests (GTTs) were performed in 4-hr-fasted
WT and Tgn male mice 5 days after treatment with
adenovirus-expressing ATGL shRNA (shATGL) or
control shRNA (shCon) (n = 4–5).
(B) Glucose tolerance: G0S2 expression. GTTs
were performed in 4-hr-fasted WT and Tgn female
mice 5 days after treatment with adenovirus-
expressing G0S2 or GFP (control) (n = 4–5).
(C) Pyruvate tolerance. Pyruvate tolerance tests
(PTTs) were performed in 4-hr-fasted WT and Tgn
mice 5 days post-ATGL KD (n = 4–5).
(D) Hepatocytes. Production of glucose from py-
ruvate and lactate was measured in hepatocytes
co-transfected with adenovirus-expressing TSS/
A-FoxO1 or GFP, plus adenovirus-expressing
ATGL shRNA (open bars) or control shRNA (solid
bars) (n = 3–4).
(E) Etomoxir. GTTs were performed in 4-hr-fasted
WT and Tgn mice 30 min after treatment with eto-
moxir or PBS (n = 4–6).
(F) Gene expression. PEPCK, G6Pase, PGC-1a,
and PCmRNA levels in liver from refed mice 5 days
after treatment with adenovirus-expressing ATGL
shRNA or control shRNA (n = 4) (see Figure S4).
Statistical significance (p < 0.05) was determined
by ANOVA and differences between groups are
identified by labeling with different letters (a, b, c,
or d), or by an asterisk for differences relative to
WT-shCon in GTT and PTT studies. Data indicate
mean ± SEM. See also Figure S4.also was increased in Tgn versus WT mice but was not depen-
dent on ATGL.
Adenoviral expression of G0S2 also restored the expression of
Gck and suppressed PEPCK expression in Tgn mice (Figures
S3C and S3D), supporting the concept that that ATGL-depen-
dent lipolysis contributes to the effects of FoxO1 on glycolytic
and gluconeogenic gene expression. In contrast, inhibition of
FAOwith etomoxir failed to disrupt effects of FoxO1 on glycolytic
(Gck, PK), lipogenic (SREBP-1c, SCD-1), or gluconeogenic
(PEPCK) gene expression in Tgn mice (Figure S5E), indicating
that FAO is not required for these ATGL-dependent effects
of FoxO1 on gene expression and that other mechanisms are
involved.
DISCUSSION
The results of this study provide several insights regarding the
role of ATGL and its inhibitor, G0S2, in mediating the effects of
FoxO proteins on gene expression and metabolism in the liver.
Key findings include the following: (1) FoxO proteins regulate
andmediate the effects of insulin on ATGL and G0S2 expression
in the liver in a cell-autonomous fashion; (2) FoxO proteins pro-
mote intrahepatic TAG catabolism and FAO in an ATGL-depen-
dent fashion; (3) ATGL-dependent FAO contributes to the effectsCof FoxO proteins on glucose homeostasis;
and (4) ATGL-dependent lipolysis also
contributes to the effects of FoxO proteinson glycolytic, lipogenic, and gluconeogenic gene expression and
metabolism. Together, these findings reveal that ATGL-depen-
dent lipolysis plays an important role in mediating the effects of
FoxO proteins on multiple aspects of glucose and lipid meta-
bolism in the liver.
We found that FoxO proteins stimulate ATGL expression in the
liver and are required for insulin to regulate ATGL in hepatocytes.
FoxO1 directly targets the ATGL promoter and promotes ATGL
expression in adipose tissue (Chakrabarti and Kandror, 2009).
While other pathways also may contribute to the ability of insulin
to regulate ATGL in adipose tissue (Chakrabarti et al., 2013), our
results indicate that FoxO proteins play a major role in regulating
and mediating the effects of insulin on ATGL expression in the
liver.
We also found that FoxO proteins suppress the expression
of G0S2 and play an important role in mediating the effects of
insulin on G0S2 expression in the liver. Insulin stimulates G0S2
expression in adipose tissue (Yang et al., 2010), yet the mecha-
nism mediating this effect has not been identified. Our data
indicate that insulin stimulates the expression of G0S2, at least
in part, by disrupting the negative effects of FoxO proteins
on G0S2 expression in the liver and, possibly, other tissues.
Interestingly, knocking down ATGL partially restored the expres-
sion of G0S2 to WT levels in FoxO1 Tgn mice, indicating thatell Reports 15, 349–359, April 12, 2016 355
Figure 6. Integrated Regulation of Glucose and Lipid Metabolism by
FoxO Proteins and ATGL-Dependent TAG Hydrolysis
(1) Previous studies have shown that FoxO proteins suppress glycolytic/lipo-
genic metabolism and promote gluconeogenic metabolism in the liver and that
insulin disrupts this effect of FoxO proteins.
(2) FoxO proteins promote ATGL and suppress G0S2 expression, as well
as promote intrahepatic lipolysis and FAO in an ATGL-dependent fashion.
Increased FAO promotes GNG and suppresses glycolytic/lipogenic meta-
bolism downstream from FoxO1 and ATGL. Reduced lipogenesis and pro-
duction of malonyl-CoA promotes increased FAO (and, thereby, glucose
production). ATGL-dependent mechanisms also contribute to the effects of
FoxO proteins on reduced glycolytic/lipogenic and increased gluconeogenic
gene expression and metabolism. Inhibition of FoxO function by insulin con-
tributes to changes in FAO, glycolysis, lipogenesis, and GNG, due, at least in
part, to ATGL-dependent effects.ATGL-dependent mechanisms contribute to the effect of FoxO
proteins on G0S2 expression and that ATGL promotes its own
activity by suppressing the expression of its inhibitor, G0S2.
ATGL-dependent lipolysis also may promote the effects of
FoxO proteins on FAO in the liver by multiple mechanisms.
For example, promoting the expression of HSL, an important
diacylglycerol lipase, would enhance intrahepatic lipolysis, and
increasing the expression of CPT1, which is required for the
translocation of long-chain fatty acyl-CoAs into the mitochon-
dria, would enhance b-oxidation. Suppression of stearoyl CoA
desaturase-1 and glycerol-3-phosphate acyltransferase would
help to ensure that free fatty acids derived from either extrahe-
patic sources or intrahepatic lipolysis would be partitioned
toward FAO rather than storage as TAGs in lipid droplets.
Further, suppressing glycolytic and lipogenic gene expression,
and lowering levels of malonyl-CoA—an important inhibitor of
CPT1—also would contribute to increased FAO. Together, these
effects would contribute to the ability of FoxO1 and ATGL to pro-
mote TAG turnover and FAO in the liver.
Our results also indicate that ATGL-dependent lipolysis and
FAO play an important role in mediating the effects of FoxO
proteins on glucose homeostasis by multiple mechanisms.
Recent studies indicate that ATGL influences hepatic glucose
metabolism (Brown et al., 2010; Ong et al., 2013; Zhang
et al., 2014). We found that FoxO1 promotes hepatic TAG turn-
over and FAO in an ATGL-dependent manner, and studies with
etomoxir showed that FAO contributes to the effects of FoxO1
on glucose homeostasis. FAO promotes GNG by providing
ATP and reducing equivalents required for glucose production,
as well as acetyl-CoA, which increases the activity of PC
(Freedman and Kohn, 1964; Perry et al., 2015; Williamson
et al., 1966). Conversely, FAO suppresses glycolysis at multi-356 Cell Reports 15, 349–359, April 12, 2016ple levels, including the activity of pyruvate dehydrogenase
(Freedman and Kohn, 1964; Garland and Randle, 1964; Hue
and Taegtmeyer, 2009). Thus, FoxO proteins may limit glycol-
ysis and the diversion of pyruvate into other pathways and
promote hepatic glucose production, at least in part, by pro-
moting FAO.
Our results also indicate that ATGL-dependent lipolysis may
play an important role in mediating the effects of FoxO1 on
gene expression related to glycolytic/lipogenic and gluconeo-
genic metabolism, including the suppression of glucokinase
and stimulation of PEPCK and PGC-1a mRNA levels. Previous
studies indicate that FoxO1 may suppress glucokinase expres-
sion by interacting with other trans-acting factors, including he-
patocyte nuclear factor-4 (Ganjam et al., 2009; Hirota et al.,
2003, 2008), and that FoxO1 can promote the expression of
PEPCK and PGC-1a expression, at least in part, through direct
interaction with cis-acting elements located in the PEPCK and
PGC-1a promoters (Daitoku et al., 2003; Hall et al., 2000; Yeag-
ley et al., 2001). The observation that the effects of FoxO1 on the
expression of these genes are largely reversed by knocking
down ATGL suggests the interesting possibility that ATGL may
function in a ‘‘feed-forward’’ fashion to promote the effects of
FoxO1 on gene expression. Although the form of FoxO1 that is
expressed in our Tgn mice (TSS/A-FoxO1) is altered so that it
is no longer subject to phosphorylation and inactivation by Akt,
its function still may be subject to regulation by other post-trans-
lational modifications, as well as other intracellular signaling
pathways that are regulated by the lipid droplet (Haemmerle
et al., 2011; Khan et al., 2015; Mullins et al., 2014; Tang et al.,
2013), and may modulate the function of FoxO proteins through
mechanisms that remain to be determined. Additional studies
are needed to determinewhether ATGL-dependentmechanisms
do, indeed, modulate the function of FoxO proteins on hepatic
gene expression and to examine the role that FoxO proteins
may play in mediating the effects of ATGL on gene expression
and metabolism in the liver.
Figure 6 summarizes some of the major findings of this study.
Previous studies indicate that FoxO proteins can suppress
glycolysis/lipogenesis and promote GNG through direct effects
on gene expression (Figure 6, number 1). As shown in Figure 6,
number 2, the results of the present study indicate that FoxO
proteins also increase ATGL and decrease G0S2 expression
and, thereby, enhance ATGL-dependent lipolysis and the avail-
ability of fatty acids for FAO in the liver. ATGL also contributes
to negative effects of FoxO on glycolytic/lipogenic gene expres-
sion andmetabolism, including the production ofmalonyl-CoA, a
negative regulator of CPT-1 activity. This suggests that ATGL-
dependent effects of FoxO proteins also may promote increased
utilization of fatty acids by disinhibiting CPT1-mediated translo-
cation of fatty acyl-CoAs into mitochondria, where b-oxidation
occurs. Since FAO is known to promote GNG and suppress
glycolysis, ATGL-dependent effects on FAO likely contribute to
the effects of FoxO proteins on glucose utilization and produc-
tion in the liver. Interestingly, ATGL also appears to contribute
to effects of TSS/A-FoxO1 on gluconeogenic gene expression,
including PEPCK and PGC-1a, which promote increased
glucose production, suggesting the intriguing possibility that
ATGL-dependent mechanisms may contribute to the regulation
of FoxO activity. At the same time, since insulin suppresses the
function of FoxO proteins, our results also suggest that regula-
tion of ATGL-dependent lipolysis may play an important role in
mediating the effects of insulin on multiple aspects of meta-
bolism in the liver, including FAO, glycolysis, lipogenesis, and
GNG.
In summary, these studies demonstrate that FoxO proteins
regulate ATGL and G0S2 expression in the liver and reveal an
important role for ATGL-dependent lipolysis in mediating the
effects of FoxO proteins on glycolytic, gluconeogenic, and lipo-
genic gene expression and metabolism in the liver. Since FoxO
proteins are major targets of insulin action, these findings also
indicate that regulation of intrahepatic lipolysis may be important
in mediating the effects of insulin on multiple aspects of glucose
and lipid metabolism in the liver and suggest that targeting
ATGL-dependent lipolysis and its downstream effectors may
provide an effective strategy for improving the treatment of
diabetes and hepatic insulin resistance.
EXPERIMENTAL PROCEDURES
Animal Studies
Animal studies were approved by the institutional animal care committees of
the Jesse Brown VA Medical Center and the University of Minnesota. Liver-
specific Tgn mice expressing a modified form of human FoxO1, in which all
three Akt phosphorylation sites (T24, S256, and S319) have been replaced
by alanine residues (TSS/A-FoxO1), were previously described (Zhang et al.,
2006). FoxO KO mice were made by crossing FoxOfl/fl mice (from Dr. Ron
DePinho) with albumin-Cre (Jackson Laboratory) mice, and disruption of liver
FoxO1, FoxO3, and FoxO4 was confirmed by real-time qPCR and western
blotting (Figures S1A–S1C). WT male FVB/N mice were purchased (Harlan
Laboratories). Studies were performed on 8- to 12-week-oldmalemice, unless
otherwise stated. Mice were housed on a 12-hr:12-hr light:dark cycle, with
lights off at 18:00. Adenoviral vectors (0.5 to 1 3 109 plaque-forming units
[pfu] per mouse) were injected by tail vein 5–7 days before studies.
For glucose and pyruvate tolerance tests, 4-hr-fasted mice were treated
with glucose (2 g/kg intraperitoneally [i.p.]) or sodium pyruvate (2 g/kg i.p.) in
PBS, or with PBS alone, and tail blood glucose levels were measured with a
OneTouch Ultra glucose meter (Lifespan) at time (t) = 0, 15, 30, 60, and
90 min. For studies in refed mice, chow was removed at 16:00 and replaced
18 hr later, and mice were sacrificed 6 hr later by decapitation following brief
sedation with isoflurane. Snap-frozen liver and serum samples from cervical
bloodwere stored at80C. To assess liver TAG secretion, micewere injected
by tail vein with Tyloxapol (350 mg/kg, Sigma-Aldrich) 4 hr after refeeding, and
serial tail blood samples were collected for analysis of TAG levels. For analysis
of de novo lipogenesis, 18-hr-fasted mice were allowed to refeed for 2 hr prior
to treatment with deuterated water (25 ml/g) and were sacrificed 4 hr later.
Hepatocytes
Primary hepatocytes were isolated by collagenase perfusion and transfected
with adenoviral vectors as previously reported (Bu et al., 2009). For studies
of insulin effects, hepatocytes were cultured in M199 media supplemented
with 10% FBS, 10 nM insulin, and 10 nM dexamethasone for 4 hr after plating,
and then in serum-free medium with or without 100 nM insulin for 4 hr, before
cell extracts were collected for analysis.
Pulse-chase studies were performed to measure TAG turnover and FAO of
fatty acids in the TAG pool, as previously described (Sapiro et al., 2009). He-
patocytes were exposed to 500 mM [1-14C]oleate for 2 hr (pulse), followed by
a 6-hr chase period with media devoid of fatty acids. Radiolabeled TAG was
quantified in cell extracts following separation by thin-layer chromatography,
and media acid-soluble metabolites (ASMs) were measured as markers of
FAO (Sapiro et al., 2009). To visualize lipid droplets, hepatocytes were har-
vested 24 hr following transfection with adenoviral vectors, rinsed with PBS,
fixed with 3.7% formaldehyde, and stained with oil red O.To measure glucose production, hepatocytes were cultured in glucose-free
DMEM without phenol red, supplemented with 20 mM sodium lactate and
2 mM sodium pyruvate (pH 7.4) and 10 nM insulin for 3 hr. Glucose concentra-
tion in medium was measured by glucose assay (Sigma) and normalized to
total protein from cell lysates.
Biochemical Analysis
Plasma levels of BHB, NEFAs, TAGs, and cholesterol were measured with
commercially available kits (Wako Chemicals). Hepatic TAG content was
measured following extraction with chloroform-methanol after the method of
Bligh and Dyer (1959). Liver acylcarnitines were measured by flow-injection
tandem mass spectrometry using a Waters Acquity UPLC System equipped
with a TQ (triple quadrupole) detector and a data system controlled by a
MassLynx 4.1 operating system (Waters), as previously described (An et al.,
2004).
Plasma lipoproteins were analyzed after fractionation by FPLC using two
Superose 6 columns linked in tandem, and 0.5-ml fractions were collected
for analysis of TAG and cholesterol concentration as previously reported
(Bu et al., 2009). Two samples from each treatment group were analyzed,
and the average is presented for each group.
Gene Expression and Western Blotting
RNA was isolated using available kits (QIAGEN), and cDNA transcripts were
prepared (SuperScript VILO) for real-time qPCR using SYBR Green. mRNA
levels were adjusted for variances in L32 ribosomal protein mRNA abundance.
Primer sequences for qPCR are shown in Table S1.
For western blotting, tissue lysates were prepared with T-Per (Pierce) sup-
plemented with protease and phosphatase inhibitors (Pierce), and protein con-
centration was quantified by the Bradford assay (Bio-Rad). Proteins were
resolved by denaturing SDS/Laemmli gel electrophoresis with 4%–15%
gradient acrylamide gels. Membranes were blocked with 5% milk in PBS
with Tween 20 (PBST) and probedwith antibodies against ATGL, tubulin, actin,
HSP90, FoxO1, or FoxO3 (Cell Signaling); glucokinase or SREBP-1c (Santa
Cruz Biotechnology) (1:1,000 dilution); G0S2, provided by Jun Liu (Yang
et al., 2010) (1:500 dilution); or apoB (Nauli et al., 2006) (1:4,000 dilution).
Results of western blotting were quantified using ImageJ software.
Statistical Analysis
Experiments were performed with three to six mice per group, and mean ±
SEM are reported. Statistical significance (p < 0.05) of differences between
groups was determined by Student’s t test when two groups were compared
or by ANOVA with post hoc testing (least mean squares) when three or more
groups were compared. When multiple groups are compared, groups that
differ significantly from each other are labeled in the figures with different
letters (a, b, c, or d), so that a is different from b; c is different from a and b;
and d is different from a, b, and c.
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